A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Oculopharyngeal Muscular Dystrophy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

NYU Langone Health, New York, New York, United States
Contact: Study coordinator (Stratos Achlatis, M.D.) · efstratios.achlatis@nyulangone.org · (646)-754-1206
Contact: Principal Investigator (Milan R. Amin, M.D.)

Study leads

Milan R. Amin, M.D.
Principal Investigator
NYU Langone Health

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Rare Disorders · Undiagnosed Disorders · Disorders of Unknown Prevalence

Abroad (travel likely)Recruiting

Sioux Falls, United States · Sydney, Australia

Oral Health, Saliva Viscosity and Composition in Oculo-Pharyngeal Muscular Dystrophy (OPMD)

Oculopharyngeal Muscular Dystrophy

IsraelRecruiting

Ramat Gan, Israel

Natural History of Oculo-Pharyngeal Muscular Dystrophy (OPMD) - Israel National OPMD Registry

Oculopharyngeal Muscular Dystrophy (OPMD)

IsraelRecruiting

Ramat Gan, Israel